Cargando…

Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

Chronic infection with hepatitis delta virus (HDV) affects between 12-20 million people worldwide and represents the most severe form of viral hepatitis, leading to accelerated liver disease progression, cirrhosis and its complications, such as end-stage-liver disease and hepatocellular carcinoma. F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lampertico, Pietro, Degasperi, Elisabetta, Sandmann, Lisa, Wedemeyer, Heiner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428117/ https://www.ncbi.nlm.nih.gov/pubmed/37593170 http://dx.doi.org/10.1016/j.jhepr.2023.100818

Ejemplares similares

Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
por: Degasperi, Elisabetta, et al.
Publicado: (2022)

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals
por: D’Ambrosio, Roberta, et al.
Publicado: (2021)

How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?
por: Loglio, Alessandro, et al.
Publicado: (2020)

Diagnosis and Management of Hepatitis Delta Virus Infection
por: Pan, Calvin, et al.
Publicado: (2023)

Correction to: Diagnosis and Management of Hepatitis Delta Virus Infection
por: Pan, Calvin, et al.
Publicado: (2023)

Proteoglycans Act as Cellular Hepatitis Delta Virus Attachment Receptors
por: Lamas Longarela, Oscar, et al.
Publicado: (2013)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam
por: Nguyen, Hung Minh, et al.
Publicado: (2017)

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
por: Marcellin, Patrick, et al.
Publicado: (2020)

Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes
por: Tham, Christine Y.L., et al.
Publicado: (2020)

Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
por: Khanam, Arshi, et al.
Publicado: (2021)

A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection
por: Lempp, Florian A., et al.
Publicado: (2021)

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon
por: D’Ambrosio, Roberta, et al.
Publicado: (2016)

The International Virus Bioinformatics Meeting 2022
por: Hufsky, Franziska, et al.
Publicado: (2022)

Development and performance of prototype serologic and molecular tests for hepatitis delta infection
por: Coller, Kelly E., et al.
Publicado: (2018)

Impfstoffe gegen Hepatitis E: Wo stehen wir?
por: Behrendt, Patrick, et al.
Publicado: (2022)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi, Elisabetta, et al.
Publicado: (2014)

Hepatitis E In Transplant Recipients: Why Is This Not A Problem In Japan?
por: Pischke, Sven, et al.
Publicado: (2015)

The New Era of Interferon-Free Treatment of Chronic Hepatitis C
por: Solbach, Philipp, et al.
Publicado: (2015)

K.02 Re-emerging epidemiology of hepatitis virus infections in Europe?
por: Wedemeyer, H.
Publicado: (2009)

Clinical Implications of HBsAg Quantification in Patients with Chronic Hepatitis B
por: Viganò, Mauro, et al.
Publicado: (2012)

Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study
por: Valenti, Luca, et al.
Publicado: (2021)

Acknowledgment to the Reviewers of Pathophysiology in 2022
Publicado: (2023)

Author Correction: Development and performance of prototype serologic and molecular tests for hepatitis delta infection
por: Coller, Kelly E., et al.
Publicado: (2020)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry
por: Tacke, Frank, et al.
Publicado: (2022)

Rolle der Hepatitis-B-Impfung in der Prävention des hepatozellulären Karzinoms
por: Dietz, Christopher A., et al.
Publicado: (2021)

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience
por: Sandmann, Lisa, et al.
Publicado: (2021)

Epidemiology of Hepatitis Delta Virus infection in HIV-infected individuals in Taiwan
por: Lin, Hsi-Hsun, et al.
Publicado: (2012)

Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery
por: Noureddin, Mazen, et al.
Publicado: (2013)

Development and evaluation of a baseline-event-anticipation score for hepatitis delta
por: Calle Serrano, B, et al.
Publicado: (2014)

Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta
por: Wranke, Anika, et al.
Publicado: (2014)

Hepatitis delta /
por: García Martín, Monserrat de los Angeles
Publicado: (1988)

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R)
por: Christensen, Stefan, et al.
Publicado: (2019)

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
por: Urban, Stephan, et al.
Publicado: (2021)

Experimental Drugs for the Treatment of Hepatitis D
por: Sandmann, Lisa, et al.
Publicado: (2021)

The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD)
por: D'Ambrosio, Roberta, et al.
Publicado: (2021)

Abstracts from the 2022 Annual Meeting of the Society of General Internal Medicine
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fl4j1grok863aeb2qrat33pip5